TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36805108

Group type: EXPERIMENTAL
Intervention: Calorie Restriction (25% reduction in energy intake)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Control (ad libitum diet)
Number of subjects: 219
Study: 36805169

Group type: EXPERIMENTAL
Intervention: Machine learning approach using smartwatch data
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Machine learning model features
Number of subjects: 22
Study: 36805181

Group type: EXPERIMENTAL
Intervention: Dietary Intervention (DI)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (before DI)
Number of subjects: 40
Study: 36805437

Group type: EXPERIMENTAL
Intervention: ag-hCG
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: atg-hCG
Number of subjects: 64

Group type: COMPARATOR
Intervention: GnRH agonist trigger
Number of subjects: 64
Study: 36805477

Group type: EXPERIMENTAL
Intervention: Less than a college degree
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Female parent gender
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Older age in years
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Greater social support scores
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Medicaid insurance
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Black race
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Higher social support
Number of subjects: 300
Study: 36805499

Group type: EXPERIMENTAL
Intervention: Imagined tastes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Food pictures dominant in specific taste qualities
Number of subjects: 0
Study: 36805537

Group type: EXPERIMENTAL
Intervention: Telomere length (TL)
Number of subjects: 137
Study: 36805552

Group type: EXPERIMENTAL
Intervention: Donanemab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 36805605

Group type: EXPERIMENTAL
Intervention: Household conflicts (general, internal, and external)
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Household conflicts (without multimorbidity)
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Household conflicts (with multimorbidity and low SES)
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Household conflicts (without multimorbidity and high SES)
Number of subjects: 1065

Group type: EXPERIMENTAL
Intervention: Frequent health complaints
Number of subjects: 1065
Study: 36805638

Group type: EXPERIMENTAL
Intervention: Composite coronary artery bypass grafting strategy (bridge)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Conventional grafting strategy
Number of subjects: 208

Group type: COMPARATOR
Intervention: Composite coronary artery bypass grafting strategy (bridge) and Conventional grafting strategy
Number of subjects: 208
Study: 36805672

Group type: EXPERIMENTAL
Intervention: Surf Therapy
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Hike Therapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Both Surf and Hike Therapies
Number of subjects: 96
Study: 36805692

Group type: EXPERIMENTAL
Intervention: Care Anywhere with Community Paramedics (CACP) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 36805694

Group type: EXPERIMENTAL
Intervention: Mindful breathing
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Prostrations (Tibetan Buddhist tradition)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Koan Mu (Zen Buddhist tradition)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Mirror exercise (Toltec tradition)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Mindfulness (control group)
Number of subjects: 240
Study: 36805707

Group type: EXPERIMENTAL
Intervention: Inhaled prostacyclin (3 times/day for 5 days)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Sodium chloride (Placebo)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Inhaled prostacyclin
Number of subjects: 150
Study: 36805758

Group type: EXPERIMENTAL
Intervention: 12-week virtual peer support programme
Number of subjects: 160

Group type: COMPARATOR
Intervention: Usual care (provision of online information resources via MND Association website)
Number of subjects: 160
Study: 36805772

Group type: EXPERIMENTAL
Intervention: sLRP1 levels
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Baseline sLRP1 levels
Number of subjects: 64
Study: 36805796

Group type: EXPERIMENTAL
Intervention: Mental well-being intervention (six face-to-face visits by psychiatric nurses after a 3-day training course)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Mental well-being intervention
Number of subjects: 87
Study: 36805833

Group type: EXPERIMENTAL
Intervention: Ato-Dro 80-5 mg
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Ato-Dro 80-10 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Atomoxetine alone
Number of subjects: 15
Study: 36806067

Group type: EXPERIMENTAL
Intervention: Preservation of the pectoral fascia (PF)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Removal of the pectoral fascia (PF)
Number of subjects: 21
Study: 36806068

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (TCS) during an AD flare
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Systemic dicloxacillin/placebo and TCS during an AD flare
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Cutaneous exposure to autologous material
Number of subjects: 81

Group type: COMPARATOR
Intervention: Untreated AD flare
Number of subjects: 81
Study: 36806073

Group type: EXPERIMENTAL
Intervention: Smartphone app (Airmid) with monthly questionnaires for 90 days
Number of subjects: 0
Study: 36806136

Group type: EXPERIMENTAL
Intervention: Combined asynchronous telemonitoring and patient-initiated follow-up
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 200
Study: 36806283

Group type: EXPERIMENTAL
Intervention: Tanezumab
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study: 36806898

Group type: EXPERIMENTAL
Intervention: Durvalumab plus tremelimumab (DT)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 160
Study: 36807080

Group type: EXPERIMENTAL
Intervention: COVID-19 infection
Number of subjects: 234

Group type: EXPERIMENTAL
Intervention: Vaccination
Number of subjects: 234
Study: 36807215

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied to the first and second molars for 10 seconds per point at 16 different points.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Contralateral side of the intervention group (no laser treatment).
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no laser treatment).
Number of subjects: 20
Study: 36807273

Group type: EXPERIMENTAL
Intervention: Ultra-long 48 mm drug-eluting stent (DES)
Number of subjects: 649

Group type: COMPARATOR
Intervention: Conventional drug-eluting stent (DES)
Number of subjects: 649
Study: 36807378

Group type: EXPERIMENTAL
Intervention: Leadless VVI
Number of subjects: 6219
Study: 36807456

Group type: EXPERIMENTAL
Intervention: Ultrathin-strut biodegradable polymer sirolimus-eluting stents (BP-SES)
Number of subjects: 1707

Group type: COMPARATOR
Intervention: Thin-strut durable polymer everolimus-eluting stents (DP-EES)
Number of subjects: 1707
Study: 36807465

Group type: EXPERIMENTAL
Intervention: Ivermectin (600 μg/kg daily for 6 days)
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1206

Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 1206
Study: 36807505

Group type: EXPERIMENTAL
Intervention: Targeted arm (risk-guided model)
Number of subjects: 4447

Group type: COMPARATOR
Intervention: Universal arm (universal offering of PrEP)
Number of subjects: 4447
Study: 36807512

Group type: EXPERIMENTAL
Intervention: Plain Balloon (PB)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Paclitaxel-coated Balloon (PCB)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting Stent (PES)
Number of subjects: 402
Study: 36807682

Group type: EXPERIMENTAL
Intervention: Electrical stimulation of cervical spinal circuits (29 days, two linear leads in the dorsolateral epidural space targeting spinal roots C3 to T1)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Continuous stimulation through selected contacts
Number of subjects: 2
Study: 36807834

Group type: EXPERIMENTAL
Intervention: Parental burden evaluated with the Experience of Caregiving Inventory
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Parental grief evaluated with the Mental Illness Version of the Texas Revised Inventory of Grief
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Fathers' burden related to their own level of anxiety
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Paternal grief related to higher anxiety and depression
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Maternal grief correlated to higher alexithymia and depression
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Paternal burden explained by father's anxiety and grief
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Maternal burden explained by mother's grief and child's clinical state
Number of subjects: 84
Study: 36808045

Group type: EXPERIMENTAL
Intervention: Web-based cognitive-behavioral therapy
Number of subjects: 17
Study: 36808075

Group type: EXPERIMENTAL
Intervention: sitravatinib 120 mg orally once daily plus tislelizumab 200 mg intravenously every 3 weeks
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: sitravatinib plus tislelizumab
Number of subjects: 122
Study: 36808074

Group type: EXPERIMENTAL
Intervention: hCART19 therapy
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: hCART19 therapy with consolidation therapy
Number of subjects: 58
Study: 36808105

Group type: EXPERIMENTAL
Intervention: Croatian version of the Self-Evaluation of Communication Experiences after Laryngectomy questionnaire (SECEL:HR)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Voice Handicap Index (VHI)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Short Form Health Survey (SF-36)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: SECEL:HR
Number of subjects: 50
Study: 36808186

Group type: COMPARATOR
Intervention: Standard treatment (rifampin and isoniazid for 24 weeks with pyrazinamide and ethambutol for the first 8 weeks)
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Initial rifampin-linezolid regimen
Number of subjects: 674

Group type: EXPERIMENTAL
Intervention: Initial bedaquiline-linezolid regimen
Number of subjects: 674
Study: 36808216

Group type: EXPERIMENTAL
Intervention: 12-g SCF + 600-mg calcium lactate gluconate (SCF + Ca)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: 12-g SCF
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: 600-mg calcium lactate gluconate (Ca)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 36808232

Group type: EXPERIMENTAL
Intervention: Kinematic parameters assessed during the 6-min walk test (6MWT)
Number of subjects: 70
Study: 36808239

Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/d
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 36808285

Group type: EXPERIMENTAL
Intervention: Nivolumab (NIVO) 3 mg/kg every 2 weeks
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Nivolumab + Ipilimumab (NIVO + IPI) 3 mg/kg + 1 mg/kg every 3 weeks (4 doses) followed by NIVO 3 mg/kg every 2 weeks
Number of subjects: 166
Study: 36808596

Group type: EXPERIMENTAL
Intervention: Clinical interventions during postoperative period
Number of subjects: 200
Study: 36808602

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks (q2w)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every week (qw)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 183
Study: 36808891

Group type: EXPERIMENTAL
Intervention: Savolitinib 600 mg (oral)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Intravenous 100 μg of radiolabeled micro-tracer
Number of subjects: 8
Study: 36808931

Group type: EXPERIMENTAL
Intervention: d-mannose (2 g/d)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (Vaginal Estrogen Therapy alone)
Number of subjects: 32
Study: 36808953

Group type: EXPERIMENTAL
Intervention: Parent-mediated interventions, specifically video modeling for parental training.
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group with no parental-training intervention.
Number of subjects: 37
Study: 36809018

Group type: EXPERIMENTAL
Intervention: mSTART (Mobile SafeTy And Recovery Therapy)
Number of subjects: 78

Group type: COMPARATOR
Intervention: START alone (without mobile augmentation)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: mSTART and START (regardless of mobile augmentation)
Number of subjects: 78
Study: 36809019

Group type: EXPERIMENTAL
Intervention: Engaging in Community Roles and Experiences (EnCoRE)
Number of subjects: 36
Study: 36809046

Group type: EXPERIMENTAL
Intervention: T-DM1
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: T-DM1 + ET
Number of subjects: 375

Group type: COMPARATOR
Intervention: trastuzumab + ET
Number of subjects: 375
Study: 36809050

Group type: EXPERIMENTAL
Intervention: Savolitinib (600 mg once daily) and Durvalumab (1,500 mg once every four weeks)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Savolitinib and Durvalumab in MET-driven patients
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Savolitinib and Durvalumab in PD-L1-positive tumors
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Savolitinib and Durvalumab
Number of subjects: 41
Study: 36809077

Group type: EXPERIMENTAL
Intervention: Near-Infrared Imaging of Indocyanine Green
Number of subjects: 0
Study: 36809080

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus pemetrexed and platinum
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 36809150

Group type: EXPERIMENTAL
Intervention: Serdexmethylphenidate/Dexmethylphenidate Capsules
Number of subjects: 0
Study: 36809187

Group type: EXPERIMENTAL
Intervention: Bremelanotide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group outcomes not specified
Number of subjects: 0
Study: 36809193

Group type: EXPERIMENTAL
Intervention: E4 15 mg
Number of subjects: 257

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study: 36809195

Group type: EXPERIMENTAL
Intervention: Setanaxib 400 mg twice daily (BID)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Setanaxib 400 mg once daily (OD)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Setanaxib 400 mg BID (moderate-to-severe fatigue at baseline)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Setanaxib 400 mg BID (mild fatigue at baseline)
Number of subjects: 111
Study: 36809199

Group type: EXPERIMENTAL
Intervention: Interventional clinical trials related to GBS
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Completed trials
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Trials in early phases (1 and 2)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Average trial duration
Number of subjects: 21
Study: 36809247

Group type: EXPERIMENTAL
Intervention: Community-administered pre-referral rectal artesunate (RAS)
Number of subjects: 7983

Group type: EXPERIMENTAL
Intervention: Parenteral antimalarial and ACT administration
Number of subjects: 7983

Group type: EXPERIMENTAL
Intervention: ACT administration at discharge
Number of subjects: 7983

Group type: EXPERIMENTAL
Intervention: Directly observed treatment
Number of subjects: 7983

Group type: EXPERIMENTAL
Intervention: Parenteral artesunate not followed up with oral ACT
Number of subjects: 7983

Group type: EXPERIMENTAL
Intervention: Pre-referral RAS
Number of subjects: 7983
Study: 36809292

Group type: EXPERIMENTAL
Intervention: Home-based HIIT intervention
Number of subjects: 47
Study: 36809294

Group type: EXPERIMENTAL
Intervention: Machine learning model using smartphone sensor data (XGBoost algorithm)
Number of subjects: 75
Study: 36809321

Group type: EXPERIMENTAL
Intervention: Aspirin discontinuation (intervention group) until delivery
Number of subjects: 936

Group type: COMPARATOR
Intervention: Aspirin continuation (control group) until 36 weeks of gestation
Number of subjects: 936

Group type: EXPERIMENTAL
Intervention: Comparison of preterm preeclampsia incidences between groups
Number of subjects: 936
Study: 36809338

Group type: EXPERIMENTAL
Intervention: VO2max assessed by cardiopulmonary exercise test (CPET) using a logarithmic function of VO2max, height, and BMI.
Number of subjects: 1141

Group type: EXPERIMENTAL
Intervention: VO2max Z-score model
Number of subjects: 1141
Study: 36809402

Group type: EXPERIMENTAL
Intervention: Visiodol (tactile pain evaluation scale)
Number of subjects: 37
Study: 36809426

Group type: EXPERIMENTAL
Intervention: Gallium 68 scanning
Number of subjects: 50
Study: 36809495

Group type: EXPERIMENTAL
Intervention: Lixisenatide
Number of subjects: 555

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 555
Study: 36809503

Group type: EXPERIMENTAL
Intervention: ePRO cohort
Number of subjects: 43

Group type: COMPARATOR
Intervention: retrospective cohort
Number of subjects: 43
Study: 36809647

Group type: EXPERIMENTAL
Intervention: Excitatory rTMS
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Inhibitory rTMS
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham stimulation (Control)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: F/M amplitude ratio
Number of subjects: 37
Study: 36809645

Group type: EXPERIMENTAL
Intervention: High-dose atropine (HDA)
Number of subjects: 11617

Group type: EXPERIMENTAL
Intervention: Medium-dose atropine (MDA)
Number of subjects: 11617

Group type: EXPERIMENTAL
Intervention: Low-dose atropine (LDA)
Number of subjects: 11617

Group type: EXPERIMENTAL
Intervention: Pirenzipine
Number of subjects: 11617

Group type: EXPERIMENTAL
Intervention: Multifocal soft contact lenses (MFSCL)
Number of subjects: 11617

Group type: EXPERIMENTAL
Intervention: Peripheral plus spectacles (PPSL)
Number of subjects: 11617

Group type: EXPERIMENTAL
Intervention: Multifocal spectacles
Number of subjects: 11617

Group type: EXPERIMENTAL
Intervention: Orthokeratology
Number of subjects: 11617

Group type: EXPERIMENTAL
Intervention: Rigid gas-permeable contact lenses (RGP)
Number of subjects: 11617

Group type: EXPERIMENTAL
Intervention: 7-methylxanthine
Number of subjects: 11617

Group type: EXPERIMENTAL
Intervention: Undercorrected single vision spectacles (SVLs)
Number of subjects: 11617

Group type: COMPARATOR
Intervention: Inactive control
Number of subjects: 11617
Study: 36809852

Group type: EXPERIMENTAL
Intervention: Whey protein (30 g); TID of AAs in whey was 97% ± 2.4% in humans and 97% ± 1.9% in pigs; if free AAs absorbed, TID would increase by 0.4%-units in humans and 0.1%-units in pigs.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Zein protein; TID of AAs in zein was 70% ± 16.4% in humans and 77% ± 20.6% in pigs; if free AAs absorbed, TID would increase by 2.3%-units in humans and 3.5%-units in pigs.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Free threonine from zein; if absorbed, TID would increase by 6.6%-units in both species (P < 0.05).
Number of subjects: 20

Group type: COMPARATOR
Intervention: No-protein diet; used as a control in the pig study.
Number of subjects: 20
Study: 36810069

Group type: EXPERIMENTAL
Intervention: MINISTOP 2.0 app
Number of subjects: 552

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 552
Study: 36810101

Group type: EXPERIMENTAL
Intervention: Fluid balance control strategy (daily weight-driven restriction of fluid intake, diuretics administration, ultrafiltration if renal replacement therapy)
Number of subjects: 1353

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1353

Group type: EXPERIMENTAL
Intervention: Fluid balance control strategy
Number of subjects: 1353
Study: 36810100

Group type: EXPERIMENTAL
Intervention: Sleep restriction (8 hours sleep deficit)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sleep deprivation (8 hours sleep deficit)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (16/8 h wake/sleep regime)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Driving performance
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Psychomotor vigilance test
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: d2 Test of Attention
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Visual attention test
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Subjective (situational) sleepiness
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Electroencephalographic changes
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Behavioral markers of sleepiness
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Changes in metabolite concentrations in exhaled breath and finger sweat
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Correlation of metabolic changes among biological matrices
Number of subjects: 24
Study: 36810120

Group type: EXPERIMENTAL
Intervention: Modified Prolonged Exposure (mPE) therapy plus Treatment as Usual (TAU)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU) alone
Number of subjects: 22
Study: 36810163

Group type: EXPERIMENTAL
Intervention: Ocrelizumab (OCR)
Number of subjects: 42
Study: 36810166

Group type: EXPERIMENTAL
Intervention: Infrapyloric (No. 206) lymph node dissection
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Greater curvature (No. 204) lymph node dissection
Number of subjects: 427

Group type: EXPERIMENTAL
Intervention: Complete mesocolic excision with central vascular ligation
Number of subjects: 427
Study: 36810168

Group type: COMPARATOR
Intervention: Standard patient therapeutic education programme (control group)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Vik-Asthme chatbot-guided training (experimental group)
Number of subjects: 80
Study: 36810173

Group type: EXPERIMENTAL
Intervention: Antimicrobial stewardship based on daily clinical assessment of clinical cure, allowing discontinuation of antibiotic therapy when at least three criteria of clinical cure are met.
Number of subjects: 590

Group type: COMPARATOR
Intervention: Standard management with a fixed duration of appropriate antibiotic therapy for 7 days according to international guidelines.
Number of subjects: 590
Study: 36810189

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-alcohol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Povidone-iodine
Number of subjects: 0
Study: 36810194

Group type: EXPERIMENTAL
Intervention: Ivermectin (400 mcg/kg) administered monthly for 3 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ivermectin (400 mcg/kg) plus livestock treatment with injectable ivermectin (200 mcg/kg) monthly for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Albendazole (400 mg) monthly for 3 months
Number of subjects: 0